---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-064473"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T11:38:38.646391+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx Q1 revenue $139M, reaffirms FY2025 guidance; UX111 PDUFA Aug 18, 2025

## Summary
- Q1 total revenue $139M (+28% YoY); net loss $151M ($1.57/share) vs $171M ($2.03) in Q1 2024.
- Crysvita revenue $103M (+25% YoY); Dojolvi $17M; Evkeeza $11M; Mepsevii $8.4M.
- Reaffirmed FY2025 guidance: total revenue $640-670M, Crysvita $460-480M, Dojolvi $90-100M.
- UX111 BLA for Sanfilippo granted Priority Review; PDUFA date Aug 18, 2025; potential H2 launch.
- DTX401 BLA for GSDIa expected mid-2025; GTX-102 Ph3 enrollment completion H2 2025; cash $563M.

## SEC filing metadata
- accession: 0000950170-25-064473
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000095017025064473/0000950170-25-064473-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000095017025064473/rare-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-064473
- JSON: https://secwatch.observer/filing/0000950170-25-064473.json
- Plain text: https://secwatch.observer/filing/0000950170-25-064473.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.